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Abstract
Purpose Data on panitumumab dosing in cancer patients with renal insufficiency are lacking. Here, we report a 63-year-old 
metastatic colorectal cancer patient with chronic kidney injury with a glomerular filtration rate of approximately 11 mL/min.
Methods Pharmacokinetic parameters, including dose-normalized area under the curve, clearance and elimination half-life 
(T1/2) after the 11th and 12th infusions were estimated using trapezoidal non-compartmental methods. Data were compared 
to previous reported pharmacokinetic data from studies in patients with normal renal function.
Results The results show that the pharmacokinetic data in this patient with kidney failure are comparable to those in patients 
with adequate renal function. Moreover the treatment was well tolerated in this patient.
Conclusion This study suggests that panitumumab can be safely used in cancer patients with renal impairment without dose 
adjustment.
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Introduction
Panitumumab is a fully humane monoclonal antibody tar-
geting the epidermal growth factor receptor (EGFR) and 
is registered for the treatment of RAS wild-type metastatic 
colorectal cancer, either alone or combined with chemo-
therapy. As previously discussed elsewhere, clearance of 
panitumumab mainly occurs by an EGFR sink. In case of 
saturation of all receptors, panitumumab will be cleared by 
immunologic mechanisms, such as complement-dependent 
cytotoxicity (CDC), antibody dependent cell-mediated cyto-
toxicity and apoptosis [1]. Therefore, theoretically renal 
insufficiency is not likely to influence the pharmacokinetics 
of panitumumab. The study of councilman et al. showed that 
nephrotic syndrome was associated with increased rituximab 
clearance, and therefore, decreased half-life. An possible 
explanation for the observed effect is loss of monoclonal 
antibody in the urine and not altered clearance [2].
The most recent summary of product characteristics 
(SmPc) of panitumumab states that a population pharma-
cokinetic analysis (among race, age, gender, hepatic func-
tion, concomitant chemotherapy and EGFR membrane-
staining intensity in tumor cells) renal function does not 
influence the pharmacokinetics of panitumumab, however, 
it is not tested in patients. The only available clinical infor-
mation concerns a case report showing safety and efficacy 
of panitumumab (combined with oxaliplatin, folic acid and 
5-FU) in a hemodialysis patient [3]. However, to our knowl-
edge, this is the first case study showing actual pharma-




A 63-year-old Caucasian male was diagnosed with colon 
cancer with hepatic metastases in November 2011. His 
medical history included diabetes type 2, congestive heart 
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failure and CKD with unknown etiology. The estimated 
clearance according to the modification of diet in renal dis-
ease (MDRD) was 21 mL/min at this time. The primary 
tumor was resected because of its obstructive character. His-
topathological analysis showed a poorly differentiated ade-
nocarcinoma, KRAS wild type. A few weeks later, the patient 
started palliative chemotherapy, consisting of oxaliplatin, 
folic acid and 5-FU (FOLFOX). This therapy was discon-
tinued after eight cycles since his renal function declined. 
After a period without treatment, he started with panitu-
mumab in May 2013. By then, his renal function had further 
declined to an estimated clearance of 11 mL/min (MDRD). 
His weight was 106 kg. Panitumumab was dosed at the rec-
ommended full dose of 6 mg/kg diluted in 100 mL sodium 
chloride solution (0.9%) and administered in 60 min, with-
out pre-medication following a standard procedure. Serum 
samples for pharmacokinetic analysis were collected after 
the 11th and 12th infusion of panitumumab and toxicity data 
were collected. The patient gave informed consent and the 
Medical Ethics Committee approved the study.
Panitumumab sampling and measuring
Serum samples were planned at 0.5, 1, 2, 4, 8, 24 h, 4 days, 
and 7 days after the 11th panitumumab infusion. Before the 
12th infusion (day 15) and 30 min, 1 h and 14 days later the 
blood samples were drawn. The samples were allowed to 
clot for 30 min, followed by centrifuging at 3000 rounds per 
minutes. The serum was transferred to a tube and stored at 
− 80 °C until analysis.
Panitumumab serum drug concentrations were performed 
by PPD laboratories (Richmond, VA, USA) using a validated 
immunoassay with electrochemiluminescence as described 
before [1].
Pharmacokinetic parameters
Pharmacokinetic parameters were estimated by trapezoi-
dal noncompartmental methods using MW/PHARM 3.5 of 
Mediware (Groningen, The Netherlands). Pharmacokinetic 
parameters for panitumumab i.e., area under the serum con-
centration–time curve (AUC) maximum observed serum 
concentration (Cmax), and minimum observed serum con-
centration (Cmin)—were determined. Half-life (T1/2), volume 
of distribution (V) and clearance (CL) were calculated.
For comparison, historical data from the summary of 
product characteristics (SPC) [2] and cohort 1 of Stephenson 
et al. were used [4]. From this study, the dose-normalized 
(for the dose of 6 mg per kg) AUC, clearance, elimination 
half-life, minimum and maximal concentrations were used. 
In case the value was within the reported serum level ± 1 
standard deviation, the found value was considered not to 
be clinically relevant or clinically different.
Toxicity
Information on toxicities were collected at baseline, just 
before each course, at the day of infusion and 7 days after 
infusion. Information on toxicities were also collected dur-
ing each unplanned hospital visit or contact. Toxicities were 
graded using CTCAE version 1.1.
Results
Case
A total of 12 infusions of panitumumab were administered. 
The patient experienced grade 2 skin toxicity, treated with 
topical agents (no minocycline because of the CKD). At the 
beginning his condition improved significantly and he had a 
mixed response with regression of liver metastases and new 
pleural metastases. However, after the 12th cycle of panitu-
mumab in the end of October 2013, his lesions had clearly 
progressed. Treatment with regorafenib was considered in 
November 2013, however, by then his CKD had progressed 
further and at that point starting dialysis seemed inevitable 
(mostly because of electrolyte disturbances). Considering 
his poor prognosis, patient declined dialysis and soon after 
that he was admitted to a hospice. He died a few weeks later.
Pharmacokinetics
The maximal observed serum concentration of panitumumab 
was 125 μg/mL after the 11th and 12th infusion. The mini-
mum concentration observed just before the 12th infusion 
was 37.0 and 48.0 μg/mL, 13 days after the 12th infusion. 
The reported serum concentrations were used to calculate 
the AUC, half-life and clearance (Table 1).
In Table 1, an overview of the pharmacokinetic parame-
ters of panitumumab in study populations with normal renal 
functions and this case is shown. In this table, the phar-
macokinetics of the 11th and 12th infusion of 6 mg/kg in 
the Stephensons cohort and data from the SPC are depicted 
and used for comparison. In Fig. 1 the time concentration 
curve after the first and second infusion of panitumumab 
are depicted.
In this case, the calculated AUC was 1555 and 1752 μg 
day/mL after the 12th infusion. The calculated clearance 
was 3.4 and 3.8 mL/day/kg and the half-life was 9.3 and 
10.8 days, respectively, after the 11th and 12th infusion. A 
comment should be made regarding the calculated half-life 
after the 12th infusion. This half-life may be biased due to 
limited sampling (at 30 min, 1 h and 14 days) because the 
distribution phase may not be terminated after one hour.
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Compared to the historical data, the maximal concentra-
tion measured in our case was lower as compared to the 
reported maximum concentration in the SPC and the Ste-
phenson’s cohort. Furthermore, the AUC calculated after 
the 12th infusion was higher in our case compared to the 
historical data. The AUC calculated after the 11th infusion 
was within the earlier reported mean and standard deviation. 
The minimum concentration, half-life and clearance calcu-
lated in this study were all comparable to the historical data 
of the cohorts and SmPC.
Discussion
Until now, no clinical studies have been conducted to exam-
ine the pharmacokinetics of panitumumab in patients with 
renal impairment. Previously, we have reported a similar 
case study with cetuximab in CKD [5] and hereby report 
one on the pharmacokinetics of panitumumab in a patient 
with CKD. During the registration of panitumumab, a popu-
lation pharmacokinetic analysis was performed to explore 
the potential effects of selected covariates on panitumumab 
pharmacokinetics. These theoretical results showed that 
renal function had no apparent impact on the pharmacoki-
netics of panitumumab. However, recommendations on dos-
ing in patients with kidney disease are lacking. Knowledge 
of the precise impact of CKD on panitumumab pharmacoki-
netics is highly relevant as the percentage of cancer patients 
over 75 years is expected to increase disproportionally [6] 
and glomerular filtration rate naturally declines during life 
[7]. In addition, most patients have previously been treated 
with oxaliplatin which may also negatively influence renal 
function. Clearly, CKD is not uncommon in colorectal can-
cer patients.
The pharmacokinetic parameters AUC and maximum 
concentrations of our case are different compared to earlier 
reported data [4]. The pharmacokinetic parameters, mini-
mum concentration, clearance and half-life were similar to 
the results reported from population without renal failure. 
It is important to mention that all the reported half lives in 
the cohorts and in the SPC are low compared to the half-life 
reported in the study of Ma et al. [8]. They reported a half-
life of 18.3 days for panitumumab. Thus, the here reported 
half lives of panitumumab (case and included studies) may 
be overestimated due to non-linear elimination shape.
The maximum concentration reported in our patient 
appeared to be lower. The weight of this patient, however, 
was 106 kg and the BMI was 30. In obese, the total blood 
volume is increased; this increase could be an explanation 
for the lower maximum concentrations of panitumumab [9].
The AUC after the 11th infusion was comparable with 
historical data. The AUC after the 12th infusion was slightly 
higher than the reported AUC’s in former studies in patients 
without renal failure. The AUC during the 11th and 12th 
infusion were estimated in steady state so this could be due 
to inter-patient variability. It is unlikely to be caused by the 
decreased renal function in this patient because clearance 
of panitumumab occurs extensively by the EGFR sink and 
Table 1  Pharmacokinetic parameters of the case and historical data from SPC and the study of Stephenson et al.
SD standard deviation
Descriptive statistic Cmax (SD) (μg/mL) Cmin (SD) (μg/mL) AUC (SD) 
(μg day/
mL)
T1/2 (SD) (days) CL (SD) (mL/day/kg) V (SD) (L)
Cohort 1 first dose 6 mg/kg (2 
weekly) [5]
152 (29.3) 18.1 (8.6) 744 (195) 5.28 (1.90) 8.21 (3.79)
Cohort 1 first dose 6 mg/kg (2 
weekly) [5]
232 (71.2) 46.6 (16.9) 1310 (375) 9.08 (3.61) 4.96 (1.49)
SPC 6 mg/kg (2 weekly) 213 (59) 39 (14) 1306 (374) 7.5 4.9
Case 11th infusion 125.0 37.0 1555 9.80 3.4 5.6

























Fig. 1  Time curve of panitumumab concentration following 1 h infu-
sion of 616 mg of panitumumab in a patient with a glomerular filtra-
tion rate (MDRD) of approximately 11 mL per minute
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the reticuloendothelial system. Another factor which may 
influence the clearance is the tumor burden and the antigen 
density of the tumor. As a consequence a lower tumor bur-
den or antigen density may lead to reduced clearance and 
thus a higher AUC.
Besides the slightly higher AUC after the 12th infusion, 
the pharmacokinetic parameters are in line with population 
without chronic kidney disease. Furthermore, during treat-
ment, no additional toxicity was noted, except the expected 
skin toxicity commonly reported in EGFR antibody treat-
ment. The absence of an effect of the renal function on the 
pharmacokinetics was as expected and in line with other 
studies. Due to their molecular size, monoclonal antibodies 
are not excreted by the urine. For panitumumab and other 
monoclonal antibodies, population pharmacokinetic studies 
used models to study the effect of the renal clearance as a 
covariate and did not find an effect on clearance [10]. In this 
study, we validated the lack of effect in a patient.
In conclusion, the pharmacokinetics of panitumumab 
between patients with decreased renal functions and patients 
with normal renal function seems similar.
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